[go: up one dir, main page]

CN101048409A - 手性8－(3－氨基－哌啶－1－基)－黄嘌呤的制备方法 - Google Patents

手性8－(3－氨基－哌啶－1－基)－黄嘌呤的制备方法 Download PDF

Info

Publication number
CN101048409A
CN101048409A CNA2005800372431A CN200580037243A CN101048409A CN 101048409 A CN101048409 A CN 101048409A CN A2005800372431 A CNA2005800372431 A CN A2005800372431A CN 200580037243 A CN200580037243 A CN 200580037243A CN 101048409 A CN101048409 A CN 101048409A
Authority
CN
China
Prior art keywords
methyl
base
phthalimido
benzyl
piperidines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2005800372431A
Other languages
English (en)
Other versions
CN101048409B (zh
Inventor
沃尔德马·弗兰格尔
索尔斯藤·帕彻
托马斯·尼古拉
阿迪尔·杜兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36010287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101048409(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Priority to CN201110002001.6A priority Critical patent/CN102127080B/zh
Priority to CN201710405988.3A priority patent/CN107266449B/zh
Priority to CN201310264236.1A priority patent/CN103351388B/zh
Publication of CN101048409A publication Critical patent/CN101048409A/zh
Application granted granted Critical
Publication of CN101048409B publication Critical patent/CN101048409B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

本发明是关于制备对映异构体性纯8－(3－氨基哌啶－1－基)－黄嘌呤的改良方法。

Description

手性8-(3-氨基-哌啶-1-基)-黄嘌呤的制备方法
技术领域
本发明涉及制备手性8-(3-氨基哌啶-1-基)-黄嘌呤、其对映异构体及其生理上可耐受盐的改良方法。
背景技术
下列通常结构的8-(3-氨基哌啶-1-基)-黄嘌呤
Figure A2005800372430006Q1
其中R1为，例如任选取代的芳基甲基或任选取代的杂芳基甲基，R2为，例如烷基，及R3为，例如任选取代的苄基或直链或支链链烯基或炔基，已从国际专利申请案WO 02/068420、WO 04/018468、WO 04/018467、WO2004/041820及WO 2004/046148中得知，其中描述了具有有价值药理性质的化合物，其包括，特别是对酶二肽基肽酶IV(DPP-IV)活性的抑制作用。因此，此类化合物适合用于预防或治疗增加的DPP-IV活性相关的疾病或症状，或其可通过降低DPP-IV活性来预防或减轻疾病或症状，特别是I型或II型糖尿病或葡萄糖耐量的降低。
WO 04/018468公开了一种制备方法，其中8-(3-氨基哌啶-1-基)-黄嘌呤是通过将相应的通式(II)的叔丁氧羰基保护的衍生物去保护来制备。
Figure A20058003724300071
在该方法中，杂质很难移除，特别是在工业级制备上会发生，这可归因于所用的保护基。因此，此方法不适合用于工业上制备8-(3-氨基哌啶-1-基)-黄嘌呤，特别是对纯度有严格要求的药品制备。再者，此方法在制备对映异构体性的纯的(enantiomerically pure)前体3-(叔丁氧羰基氨基)哌啶上具有复杂且昂贵的缺点。然而，由于副作用的风险及将剂量降至最低的考虑，对映异构体性纯的活性物质对医药的应用是优选的。这些情况对该现知的工业制备对映异构性纯8-(3-氨基哌啶-1-基)-黄嘌呤的适用性为不利的。
考虑了上述该已知制备方法的缺点，本发明的目的是提供一种使用易得的高化学纯及光学纯的起始物质，及无高技术成本及不便性下制备对映异构体性纯的8-(3-氨基哌啶-1-基)-黄嘌呤的方法。该新颖方法亦适用于工业级合成，因此可作为商业应用。
此目的可通过以本发明的方法制备手性8-(3-氨基哌啶-1-基)-黄嘌呤来达到。除了高产率的工业可行性外，绝佳的化学及光学纯度为本发明合成路径的其他的优点。
发明内容
根据本发明的方法，适当的黄嘌呤前体(III)是根据流程1的对映异构体性纯的或外消旋的(3-苯二甲酰亚氨基(phthalimido))-哌啶，在适当的溶剂中于20至160℃、优选为80至140℃的温度下反应。所用的溶剂，例如可为四氢呋喃(THF)、二烷、N，N-二甲基甲酰胺(DMF)、二甲基乙酰胺(DMA)、N-甲基-2-吡咯烷酮(NMP)或二甲基亚砜(DMSO)。优选的是使用NMP。随后以本身已知的方法将邻苯二甲酰基保护基除去。可能的除去方法是描述于，例如T.W.Greene的“Protective Groups in Organic Synthesis”，Wiley 1981，第265页(例如溶于乙醇中的肼)。
Figure A20058003724300081
在上述的化学式中，
X为离去基团，其是选自卤素，例如氟、氯或溴原子，或磺酸酯，例如苯基磺酰基氧基、对甲苯磺酰基氧基、甲基磺酰基氧基或三氟甲基磺酰基氧基的基团。
R1为苯基羰基甲基、苄基、萘基甲基、吡啶基甲基、嘧啶基甲基、喹啉基甲基，异喹啉基甲基、喹唑啉基甲基、喹喔啉基甲基、萘啶基甲基或菲啶基甲基，其中芳族或杂芳族基团在各情况下被Ra单或二取代，而该取代基可为相同或不同，及
Ra为氢、氟、氯或溴原子或氰基、甲基、三氟甲基、乙基、苯基、
甲氧基、二氟甲氧基、三氟甲氧基或乙氧基，
或二个Ra基，当它们与相邻的碳原子键结时，还可为-O-CH2-O-或-O-CH2-CH2-O-基，
R2为甲基、乙基、丙基、异丙基、环丙基或苯基及
R3为2-丁烯-1-基、3-甲基-2-丁烯-1-基、2-丁炔-1-基、2-氟苄基、2-氯苄基、2-溴苄基、2-碘苄基、2-甲基苄基、2-(三氟甲基)苄基或2-氰基苄基。
该方法优选的是用于这些化合物，其中
X为氯或溴原子，
R1为苯基羰基甲基、苄基、萘基甲基、吡啶基甲基、嘧啶基甲基、喹啉基甲基，异喹啉基甲基、喹唑啉基甲基、喹喔啉基-甲基或萘啶基甲基，其中芳族或杂芳族基团在各情况下被Ra单或二取代，而该取代基可为相同或不同，及
Ra为氢、氟或氯原子或氰基、甲基、乙基、甲氧基或乙氧基，
R2为甲基、乙基、丙基、异丙基、环丙基或苯基及
R3为2-丁烯-1-基、3-甲基-2-丁烯-1-基、2-丁炔-1-基、2-氟苄基、2-氯苄基、2-溴苄基、2-碘苄基、2-甲基苄基、2-(三氟甲基)苄基或2-氰基苄基基团。
该方法优选的是用于那些化合物，其中
X为氯或溴原子
R1为氰基苄基、(氰基吡啶基)甲基、喹啉基甲基，(甲基喹啉基)甲基、异喹唑啉基甲基、(甲基异喹啉基)甲基、喹唑啉基甲基、(甲基喹唑啉基)甲基、喹喔啉甲基、(甲基喹喔啉基)甲基、(二甲基喹喔啉基)甲基或萘啶基甲基，
R2为甲基、环丙基或苯基及
R3为2-丁烯-1-基、3-甲基-2-丁烯-1-基、2-丁炔-1-基、2-氯苄基、2-溴苄基或2-氰基苄基，
但特别是对化合物1-[(4-甲基喹唑啉-2-基)甲基]-3-甲基-7-(2-丁炔-1-基)-8-(3-(R)-氨基哌啶-1-基)-黄嘌呤、1-[(3-甲基异喹啉-1-基)甲基]-3-甲基-7-(2-丁炔-1-基)-8-((R)-3-氨基哌啶-1-基)-黄嘌呤及1-[(3-氰基哌啶-2-基)甲基]-3-甲基-7-(2-丁炔-1-基)-8-(3-(R)-氨基哌啶-1-基)-黄嘌呤，其中X为溴。
在各情况下优选的是使用(R)-3-(苯二甲酰亚氨基)哌啶作为试剂。式(III)化合物的制备已描述于上述引用的文献中，且可根据已知的方法来进行。
本发明还提供制备光学活性3-(苯二甲酰亚氨基)哌啶的方法。在此方法中，先将3-氨基吡啶根据已知的方法氢化。然后将由此得到的外消旋3-氨基哌啶通过邻苯二甲酸酐转变为相应的邻苯二甲酰亚胺。从外消旋、粗邻苯二甲酰亚胺(IV)溶液中通过D-酒石酸可选择性地沉淀出该(R)对映异构体。毋须先将原来存在母液中的过量的D-酒石酸移除，以简单方法通过添加L-酒石酸还可由盐沉淀的母液中得到(IV)的(S)对映异构体。
此极简单的式(IV)化合物的对映异构体的分离，令本领域技术人员非常惊讶。由氢化反应得来的外消旋碱不必预先纯化来达到此目的。该方法本身甚至在工业级制备仍无任何问题。
此外，3-氨基哌啶与邻苯二甲酸酐的出乎意料完全的反应本身令人惊讶，因为根据文献(例如美国专利4,005,208，特别是实施例27)，除了所需的产物外，混合物中预期会含有环上氮原子被酰化的衍生物。
Figure A20058003724300101
下列实施例将更详细的说明本发明：
实施例1：
3-(苯二甲酰亚氨基)哌啶的R对映异构体的D-酒石酸盐
a.氢化作用：
将10.00kg(106.25mol)的3-氨基吡啶、500g工业级的活性炭及65升醋酸先装入氢化反应器中。将50g的Nishimura催化剂(市售的铑/铂混合催化剂)加入2.5升的醋酸中形成浆液并冲入(flush in)2.5升的醋酸。于50℃及100bar的氢气压下进行氢化，直到停止吸收氢气，及随后于50℃进行后氢化(post-hydrogenation)反应30分钟。将催化剂及活性炭滤出并以10升的醋酸洗涤。毋须纯化将产物溶液进行进一步的反应。
反应亦可在较不严格的压力下进行。
b.酰化作用
Figure A20058003724300111
先将15.74kg(106.25mol)的邻苯二甲酸酐装入反应器中。并与由氢化反应得来的滤液混合。将其冲入7.5升的醋酸并随后将反应混合物加热回流，在此期间一小时内，蒸馏出约30％所用的醋酸。将反应溶液冷却至90℃。毋须纯化将产物溶液进行进一步的反应。
c.旋光拆开
Figure A20058003724300112
将加热至50℃的11.16kgD(-)-酒石酸(74.38mol)的50升的无水乙醇溶液于90℃计量加入酰化反应溶液中。将其中冲入10升的无水乙醇并于90℃搅拌30分钟，在此期间产物结晶出。冷却至5℃后，将产物离心及以无水乙醇洗涤。毋须纯化将产物溶液进行进一步的反应。
d.重结晶
将湿的粗产物置于50升丙酮及90升水的混合物中加热回流直到溶液形成。随后，溶液冷却至5℃，在此期间有产物结晶出。将悬浮液于5℃搅拌30分钟，并将产物离心，最后用20升丙酮和10升水的混合物洗涤。将混合物在45℃在惰性条件下在干燥箱中干燥。
产率：11.7-12.5kg(理论值的29-31％)
实施例2
合成1-[(4-甲基喹唑啉-2-基)甲基]-3-甲基-7-(2-丁炔-1-基)-8-(3-(R)-氨基哌啶-1-基)-黄嘌呤
a.2-氯甲基-4-甲基喹唑啉
Figure A20058003724300121
先装入10.00kg(73.98mol)的2-氨基苯乙酮并加入24.5升的1，4-二烷。将溶液冷却至10℃，与引入的16.72kg(458.68mol)的氯化氢混合。将反应混合物加温至22-25℃。于此温度下再引入氯化氢。约至总引入量的一半时，混合物冷却至-10℃并继续引入。随后，将形成的悬浮液放置于-10℃下过夜。于-10℃，一小时内加入6.70kg(88.78mol)氯乙腈的2.5升1，4-二烷溶液。向原料容器(feed vessel)冲入2升的1，4-二烷。之后，将反应器的内容物加温至6℃并再搅拌约2小时。
先向另一反应器中装入122升水及62.04kg(775.31mol)氢氧化钠溶液(50％)的混合物并冷却至6℃。分次加入第一反应器的反应混合物。内部的温度不超过11℃。随后，首先将第一反应器用6升1，4-二烷冲洗，然后用6升的水冲洗。将生成的悬浮液于5℃再搅拌30分钟。将产物离心，以41升的水洗涤并于35℃在惰性条件下在干燥箱中干燥。
产率：10.5-12.1kg(理论值的74-85％)
b.1-[(4-甲基喹唑啉-2-基)甲基]-3-甲基-7-(2-丁炔-1-基)-8-溴黄嘌呤
Figure A20058003724300122
将10.00kg(33.66mol)的3-甲基-7-(2-丁炔-1-基)-8-溴黄嘌呤、7.13kg(37.02mol)2-氯甲基-4-甲基喹唑啉、3.92kg(37.02mol)无水碳酸钠及30升N-甲基-2-吡咯烷酮先装入反应器中。将反应器内容物加热至140℃并于140℃搅拌2小时。反应结束后，将反应混合物冷却至80℃并用60升的96％乙醇稀释，随后于70℃用55升的水稀释。于60℃，计量加入4.04kg(67.32mol)醋酸并冲入5升的水。将生成的悬浮液于60℃搅拌30分钟，然后冷却至23℃并再搅拌30分钟。随后将产物离心并先以20升96％乙醇及20升水的混合物洗涤，然后以40升96％乙醇及40升水的混合物洗涤。于45℃在惰性条件下(under inertization)在干燥箱中干燥。
产率：11.6-12.6kg(理论值的76-83％)
c.1-[(4-甲基喹唑啉-2-基)甲基]-3-甲基-7-(2-丁炔-1-基)-8-(3-(R)-苯二甲酰亚氨基哌啶-1-基)-黄嘌呤
Figure A20058003724300131
将10.00kg(22.06mol)的1-[(4-甲基喹唑啉-2-基)甲基]-3-甲基-7-(2-丁炔-1-基)-8-溴黄嘌呤、12.59kg(33.09mol)的3-(苯二甲酰亚氨基)哌啶D-酒石酸盐及17.5升的N-甲基-2-吡咯烷酮先装入反应器中。将反应器内容物加热至140℃。达到此温度后，于20分钟内计量加入11.41kg(88.24mol)的二异丙基乙胺。向原料容器中冲入2.5升的N-甲基-2-吡咯烷酮及随后将反应混合物于140℃搅拌2小时。反应结束后，将反应混合物冷却至60℃并以80升的甲醇稀释。将生成的悬浮液于50℃搅拌30分钟，然后冷却至23℃并再搅拌30分钟。随后将产物离心并各以20升的甲醇洗涤3次。于45℃在惰性条件下在干燥箱中干燥。
产率：12.0-12.5kg(理论值的90-94％)
d.1-[(4-甲基喹唑啉-2-基)甲基]-3-甲基-7-(2-丁炔-1-基)-8-(3-(R)-氨基哌啶-1-基)-黄嘌呤
将1800kg(3mol)的1-[(4-甲基喹唑啉-2-基)甲基]-3-甲基-7-(2-丁炔-1-基)-8-(3-(R)-苯二甲酰亚氨基哌啶-1-基)-黄嘌呤于18升的甲苯中加热至80-85℃。随后，于75-80℃将1.815升(30mol)的乙醇胺加到悬浮液中。将混合物于80-85℃搅拌2小时使反应完全，在此期间有固体进入溶液中。随后进行相分离。用温热的甲苯洗涤乙醇胺层二次(每次4升)。将合并的甲苯层每次各以8升的水于75-80℃洗涤二次。将22升的甲苯于减压下由甲苯层中蒸馏出。于40-50℃计量4升的叔丁基甲醚加至生成的悬浮液中并随后冷却至0-5℃。经过滤分离出产物，用叔丁基甲醚洗涤并抽真空干燥(suctiondry)。之后将湿的粗物质与5倍量的无水乙醇加热回流并将该热溶液经活性炭过滤净化。将滤液冷却至20℃后，开始结晶，将其用叔丁基甲基醚稀释成二倍体积。将悬浮液冷却至2℃，另再搅拌2小时，抽滤并于45℃在真空干燥箱中干燥。
产率：1174g(理论值的83.2％)
步骤d的另一种方法：
将1400kg(2.32mol)的1-[(4-甲基喹唑啉-2-基)甲基]-3-甲基-7-(2-丁炔-1-基)-8-(3-(R)-苯二甲酰亚氨基哌啶-1-基)-黄嘌呤先置入4.9升的四氢呋喃中，随后加热至55-65℃。之后，将350ml的水及1433g(2.32mol)的乙醇胺加到悬浮液中。将混合物于60-63℃再搅拌3小时使反应完全。之后，加入619ml的45％的氢氧化钠溶液及3.85升的水，并将混合物于55-65℃搅拌30分钟，然后向反应混合物中加入5.6升的甲苯，将混合物搅拌15分钟，之后进行相分离。以2.8升的水于55-65℃洗涤有机层，随后分离。减压下从有机层蒸馏出4.2升。之后，于65-75℃加入1.4升的甲基环己烷，在此期间产物结晶。将悬浮液在15-25℃搅拌8-16小时，然后冷却至0-5℃。将产物过滤分离，用4.2升的甲基环己烷洗涤，抽真空干燥并于35℃减压干燥。随后将干燥的粗物质(991g)与5倍量的甲醇加热回流，加入活性炭并过滤混合物。将甲醇蒸馏出使滤液体积降至1.5升。将滤液冷却至45-55℃后，以叔丁基甲醚稀释成四倍体积。悬浮液冷却至0-5℃，搅拌2小时，抽滤、用叔丁基甲醚洗涤并于35℃在真空干燥箱中干燥。
产率：899g(81.9％的理论值)
实施例3
1-[(3-氰基-吡啶-2-基)甲基]-3-甲基-7-(2-丁炔-1-基)-8-(3-(R)-氨基-哌啶-1-基)-黄嘌呤
a.3-氰基-2-(氯甲基)-吡啶
将165.5g(0.98mol)的2-羟基甲基-3-吡啶甲酰胺(pyridinecarboxamide)与270ml的三氯氧化磷(phosphorus oxychloride)共同于90-100℃加热1小时。将反应混合物冷却至室温及随后于50-60℃逐滴加入约800ml的水。待三氯氧化磷水解后，冷却下以氢氧化钠溶液中和，在此期间沉淀出产物。将其过滤，以300ml的水洗涤及随后于35-40℃下干燥。
产率：122.6g(理论值的82％)
步骤a的另一种方法：3-氰基-2-(氯甲基)吡啶
将20.0g(131.45mmol)的2-羟基甲基-3-吡啶甲酰胺悬浮于110ml的乙腈中并加热至78℃。于15分钟内，计量加入60.65g(395.52mmol)的三氯氧化磷至混合物中并将混合物于81℃加热2小时。于22℃冷却后，将反应混合物置于200ml的水中于40℃下搅拌。加入100ml的甲苯后，以氢氧化钠溶液冷却下中和。进行相分离后，以100ml的水洗涤有机层。移出有机层并减压蒸发溶剂得到起初生成的油状残留物，将其静置使其结晶。
产率：16.66g(理论值的83％)
b.1-[(3-氰基-吡啶-2-基)甲基]-3-甲基-7-(2-丁炔-1-基)-8-溴黄嘌呤
Figure A20058003724300151
将202g(0.68mol)的3-甲基-7-(2-丁炔-1-基)-8-溴黄嘌呤、188.5g(1.36mol)的无水碳酸钾及1.68升的N-甲基-2-吡咯烷酮(pyrrolidone)先装入反应器中并加热至70℃。随后，逐滴加入119g(0.75mol)的2-氯甲基-3-氰基吡啶的240ml的N-甲基-2-吡咯烷酮(pyrrolidine)(NMP)溶液。将反应器内容物于70℃下搅拌19小时。待反应结束后，将2.8升的水加到反应混合物中并冷却至25℃。将产物过滤出，以2升的水洗涤并于70℃在惰性条件下在干燥箱中干燥。
产率：257.5g(理论值的91％)
c.1-[(3-氰基-吡啶-2-基)甲基]-3-甲基-7-(2-丁炔-1-基)-8-(3-(R)-苯二甲酰亚氨基哌啶-1-基)-黄嘌呤
Figure A20058003724300161
将230g(0.557mol)的1-[(3-氰基-吡啶-2-基)甲基]-3-甲基-7-(2-丁炔-1-基)-8-溴黄嘌呤、318g(0.835mol)的3-(苯二甲酰亚氨基)哌啶D-酒石酸盐及1.15升的N-甲基-2-吡咯烷酮先装入反应器中。将反应器内容物加热至140℃。待达到此温度后，在20分钟内计量加入478ml(2.78mol)的二异丙基乙胺，随后将反应混合物于140℃搅拌2小时。之后，将反应混合物冷却至75℃并以720ml的甲醇稀释，之后，于68-60℃加入2.7升水并将混合物冷却至25℃。将产物过滤出并以2升的水洗涤。于70℃在惰性条件下在干燥箱中进行干燥。
之后将得到的粗产物置于1升的甲醇中煮沸搅拌，热过滤，以200ml的甲醇冲洗，随后于70℃惰性条件下干燥。
产率：275g(理论值的88％)
d.1-[(3-氰基-吡啶-2-基)甲基]-3-甲基-7-(2-丁炔-1-基)-8-(3-(R)-氨基哌啶-1-基)-黄嘌呤
Figure A20058003724300171
将412.5g(0.733mol)的1-[(3-氰基-吡啶-2-基)甲基]-3-甲基-7-(2-丁炔-1-基)-8-(3-(R)-苯二甲酰亚氨基哌啶-1-基)-黄嘌呤于4125ml的甲苯中加热至80℃。随后于75-80℃将445ml的乙醇胺(7.33mol)加到悬浮液中。将混合物于80-85℃再搅拌2小时，使反应完全，在此期间有固体进入溶液中。之后，进行相分离。将乙醇胺相用温甲苯萃取二次(每次1升)。将合并的甲苯相于75-80℃以每次2升的水洗涤二次。用硫酸钠干燥甲苯相，过滤并随后于减压下蒸馏将体积降至约430ml。之后于50-55℃计量加入1升的叔丁基甲醚，然后将混合物冷却至0-5℃。将产物过滤分离，用叔丁基甲醚洗涤并于60℃在干燥箱中干燥。
产率：273g(理论值的86％)
熔点：188±3℃
类似实施例2及3，还制备出1-[(3-甲基异喹啉-1-基)甲基]-3-甲基-7-(2-丁炔-1-基)-8-((R)-3-氨基-哌啶-1-基)-黄嘌呤。

Claims (14)

1.一种制备通式(I)化合物或其对映异构体或其盐的方法
Figure A2005800372430002C1
其中R1为苯基羰基甲基、苄基、萘基甲基、吡啶基甲基、嘧啶基甲基、喹啉基甲基，异喹啉基甲基、喹唑啉基甲基、喹喔啉基甲基、萘啶基甲基或菲啶基甲基，其中芳族或杂芳族基团在各情况下被Ra单或双取代，而该取代基可为相同或不同，及
Ra为氢、氟、氯或溴原子或氰基、甲基、三氟甲基、乙基、苯基、甲氧基、二氟甲氧基、三氟甲氧基或乙氧基，
或二个Ra基，当与相邻的碳原子连接时，还可为-O-CH2-O-或-O-CH2-CH2-O-基，
R2为甲基、乙基、丙基、异丙基、环丙基或苯基及
R3为2-丁烯-1-基、3-甲基-2-丁烯-1-基、2-丁炔-1-基、2-氟苄基、2-氯苄基、2-溴苄基、2-碘苄基、2-甲基苄基、2-(三氟甲基)苄基或2-氰基苄基，
所述方法包括下列合成步骤：
a)将通式(III)的化合物与3-(苯二甲酰亚氨基)哌啶或其对映异构体反应，
Figure A2005800372430002C2
其中X为离去基团，其选自卤素或磺酸酯，及
R1至R3各如上述的定义，
b)将得到的通式(II)化合物去保护
其中R1至R3各如上述定义，及
c)任选转变为生理上可耐受的盐。
2.根据权利要求1所述的方法，其中
X为氯或溴原子
R1为苯基羰基甲基、苄基、萘基甲基、吡啶基甲基、嘧啶基甲基、喹啉基甲基，异喹啉基甲基、喹唑啉基甲基、喹喔啉基甲基或萘啶基甲基，其中芳族或杂芳族基团在各情况下被Ra单或双取代，而该取代基可为相同或不同，及
Ra为氢、氟或氯原子或氰基、甲基、乙基、甲氧基或乙氧基，
R2为甲基、乙基、丙基、异丙基、环丙基或苯基及
R3为2-丁烯-1-基、3-甲基-2-丁烯-1-基、2-丁炔-1-基、2-氟苄基、2-氯苄基、2-溴苄基、2-碘苄基、2-甲基苄基、2-(三氟甲基)苄基或2-氰基苄基。
3.根据权利要求2所述的方法，其中
X为氯或溴原子
R1为氰基苄基、(氰基吡啶基)甲基、喹啉基甲基，(甲基喹啉基)甲基、异喹啉基甲基、(甲基异喹啉基)甲基、喹唑啉基甲基、(甲基喹唑啉基)甲基、喹喔啉甲基、(甲基喹喔啉基)甲基、(二甲基喹喔啉基)甲基或萘啶基甲基，
R2为甲基、环丙基或苯基及
R3为2-丁烯-1-基、3-甲基-2-丁烯-1-基、2-丁炔-1-基、2-氯苄基、2-溴苄基或2-氰基苄基。
4.根据权利要求3所述的方法，其中
X为溴原子，
R1为(4-甲基喹唑啉-2-基)甲基，(3-甲基异喹啉-1-基)甲基或(3-氰基吡啶-2-基)甲基，
R2为甲基及
R3为2-丁炔-1-基。
5.根据权利要求1至4中任一项所述的方法，其中用于步骤a)的反应物为(R)-3-(苯二甲酰亚氨基)哌啶。
6.一种制备(R)-3-(苯二甲酰亚氨基)哌啶的方法，其包括下列合成步骤：
a)将外消旋-3-氨基哌啶于适当的溶剂中与邻苯二甲酸酐反应，及
b)通过加入D-酒石酸并分离沉淀的酒石酸盐，从得到的外消旋-3-(苯二甲酰亚氨基)哌啶的溶液中分离出(R)-3-(苯二甲酰亚氨基)哌啶。
7.一种制备(S)-3-(苯二甲酰亚氨基)哌啶的方法，其包括下列合成步骤：
a)将外消旋-3-氨基哌啶于适当的溶剂中与邻苯二甲酸酐反应，及
b)通过加入L-酒石酸及分离沉淀的酒石酸盐，从得到的外消旋-3-(苯二甲酰亚氨基)哌啶的溶液中分离出(S)-3-(苯二甲酰亚氨基)哌啶。
8.一种制备(S)-3-(苯二甲酰亚氨基)哌啶的方法，其包括下列合成步骤：
a)将外消旋-3-氨基哌啶于适当的溶剂中与邻苯二甲酸酐反应，及
b)通过加入D-酒石酸并分离沉淀的酒石酸盐，从得到的外消旋-3-(苯二甲酰亚氨基)哌啶的溶液中分离出(R)-3-(苯二甲酰亚氨基)哌啶，及
c)将L-酒石酸加至由第一次盐沉淀所得到的母液中并分离出沉淀的(S)-3-(苯二甲酰亚氨基)哌啶酒石酸盐。
9.根据权利要求6至8中任一项所述的方法，其中用于步骤b)中的溶剂为乙醇。
10.(R)-3-(苯二甲酰亚氨基)哌啶。
11.(S)-3-(苯二甲酰亚氨基)哌啶。
12.下列通式的化合物，或其对映异构体，或其一种盐，
Figure A2005800372430005C1
其中R1至R3各如权利要求1至4定义，其可通过根据权利要求1至5中任一项所述的方法得到。
13.药物，其包含如权利要求12所述的化合物及任选一或多种惰性载体及/或稀释剂。
14.如权利要求12所述的化合物在制备适合治疗I型及II型糖尿病、糖尿病前期或葡萄糖耐量降低、关节炎、肥胖症、同种异体移植及降钙素引起的骨质疏松症的药物中的用途。
CN200580037243.1A 2004-11-05 2005-11-02 手性8-（3-氨基-哌啶-1-基）-黄嘌呤的制备方法 Expired - Lifetime CN101048409B (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201110002001.6A CN102127080B (zh) 2004-11-05 2005-11-02 手性8-(3-氨基-哌啶-1-基)-黄嘌呤的制备方法
CN201710405988.3A CN107266449B (zh) 2004-11-05 2005-11-02 手性8-(3-氨基-哌啶-1-基)-黄嘌呤的制备方法
CN201310264236.1A CN103351388B (zh) 2004-11-05 2005-11-02 手性8-(3-氨基-哌啶-1-基)-黄嘌呤的制备方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004054054.3 2004-11-05
DE102004054054A DE102004054054A1 (de) 2004-11-05 2004-11-05 Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
PCT/EP2005/055711 WO2006048427A1 (de) 2004-11-05 2005-11-02 Verfahren zur herstellung chiraler 8-(3-amino-piperidin-1-yl)-xanthine

Related Child Applications (5)

Application Number Title Priority Date Filing Date
CN201310264236.1A Division CN103351388B (zh) 2004-11-05 2005-11-02 手性8-(3-氨基-哌啶-1-基)-黄嘌呤的制备方法
CN2011103540629A Division CN102391267A (zh) 2004-11-05 2005-11-02 8-(3-氨基-哌啶-1-基)-黄嘌呤、其制备方法及其用途
CN201710405988.3A Division CN107266449B (zh) 2004-11-05 2005-11-02 手性8-(3-氨基-哌啶-1-基)-黄嘌呤的制备方法
CN201110002001.6A Division CN102127080B (zh) 2004-11-05 2005-11-02 手性8-(3-氨基-哌啶-1-基)-黄嘌呤的制备方法
CN2011103551125A Division CN102432593A (zh) 2004-11-05 2005-11-02 光学活性的3-(邻苯二甲酰亚氨基)哌啶及其制备方法

Publications (2)

Publication Number Publication Date
CN101048409A true CN101048409A (zh) 2007-10-03
CN101048409B CN101048409B (zh) 2014-01-22

Family

ID=36010287

Family Applications (6)

Application Number Title Priority Date Filing Date
CN200580037243.1A Expired - Lifetime CN101048409B (zh) 2004-11-05 2005-11-02 手性8-（3-氨基-哌啶-1-基）-黄嘌呤的制备方法
CN2011103551125A Pending CN102432593A (zh) 2004-11-05 2005-11-02 光学活性的3-(邻苯二甲酰亚氨基)哌啶及其制备方法
CN201310264236.1A Expired - Lifetime CN103351388B (zh) 2004-11-05 2005-11-02 手性8-(3-氨基-哌啶-1-基)-黄嘌呤的制备方法
CN201710405988.3A Expired - Lifetime CN107266449B (zh) 2004-11-05 2005-11-02 手性8-(3-氨基-哌啶-1-基)-黄嘌呤的制备方法
CN201110002001.6A Expired - Lifetime CN102127080B (zh) 2004-11-05 2005-11-02 手性8-(3-氨基-哌啶-1-基)-黄嘌呤的制备方法
CN2011103540629A Pending CN102391267A (zh) 2004-11-05 2005-11-02 8-(3-氨基-哌啶-1-基)-黄嘌呤、其制备方法及其用途

Family Applications After (5)

Application Number Title Priority Date Filing Date
CN2011103551125A Pending CN102432593A (zh) 2004-11-05 2005-11-02 光学活性的3-(邻苯二甲酰亚氨基)哌啶及其制备方法
CN201310264236.1A Expired - Lifetime CN103351388B (zh) 2004-11-05 2005-11-02 手性8-(3-氨基-哌啶-1-基)-黄嘌呤的制备方法
CN201710405988.3A Expired - Lifetime CN107266449B (zh) 2004-11-05 2005-11-02 手性8-(3-氨基-哌啶-1-基)-黄嘌呤的制备方法
CN201110002001.6A Expired - Lifetime CN102127080B (zh) 2004-11-05 2005-11-02 手性8-(3-氨基-哌啶-1-基)-黄嘌呤的制备方法
CN2011103540629A Pending CN102391267A (zh) 2004-11-05 2005-11-02 8-(3-氨基-哌啶-1-基)-黄嘌呤、其制备方法及其用途

Country Status (34)

Country Link
US (6) US7820815B2 (zh)
EP (4) EP2287164B9 (zh)
JP (3) JP5063356B2 (zh)
KR (3) KR101383610B1 (zh)
CN (6) CN101048409B (zh)
AR (1) AR051947A1 (zh)
AU (1) AU2005300559B2 (zh)
BR (1) BRPI0517093B8 (zh)
CA (1) CA2586938C (zh)
CY (1) CY1115036T1 (zh)
DE (1) DE102004054054A1 (zh)
DK (2) DK2287164T5 (zh)
EA (3) EA029039B1 (zh)
ES (2) ES2731334T3 (zh)
HR (1) HRP20140373T2 (zh)
HU (1) HUE044308T2 (zh)
IL (2) IL182923A (zh)
ME (1) ME01667B (zh)
MX (2) MX2007005404A (zh)
MY (1) MY145604A (zh)
NO (1) NO20071522L (zh)
NZ (3) NZ589450A (zh)
PE (2) PE20060921A1 (zh)
PL (2) PL2287164T3 (zh)
PT (1) PT2287164E (zh)
RS (1) RS53166B (zh)
SG (3) SG185967A1 (zh)
SI (1) SI2287164T1 (zh)
TR (1) TR201908974T4 (zh)
TW (2) TWI374885B (zh)
UA (1) UA100221C2 (zh)
UY (1) UY29190A1 (zh)
WO (1) WO2006048427A1 (zh)
ZA (1) ZA200701996B (zh)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102372691A (zh) * 2011-11-15 2012-03-14 海门慧聚药业有限公司 (r)-3-苯二甲酰亚胺哌啶酒石酸盐的制备工艺
CN102516225A (zh) * 2011-11-18 2012-06-27 海门慧聚药业有限公司 新型医药中间体(r)-3-苯二甲酰亚胺哌啶盐酸盐的合成
CN103450201A (zh) * 2012-05-30 2013-12-18 博瑞生物医药技术(苏州)有限公司 手性8-（3-氨基哌啶-1-基）-黄嘌呤的制备方法
CN103781788A (zh) * 2011-07-15 2014-05-07 勃林格殷格翰国际有限公司 经取代的喹唑啉、其制备及其在药物组合物中的用途
WO2014033746A3 (en) * 2012-08-17 2014-05-30 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of dipeptidylpeptidase inhibitors
CN104478880A (zh) * 2014-12-26 2015-04-01 浙江永太科技股份有限公司 作为dpp-iv抑制剂的双胍衍生物
CN104478879A (zh) * 2014-12-26 2015-04-01 浙江永太科技股份有限公司 一种作为二肽基肽酶-4抑制剂的化合物
CN104557935A (zh) * 2015-01-27 2015-04-29 江苏嘉逸医药有限公司 制备(r)-8-(3-氨基哌啶-1-基)-黄嘌呤的提纯方法
CN104592234A (zh) * 2014-12-26 2015-05-06 浙江永太科技股份有限公司 一种作为二肽基肽酶-4抑制剂的化合物的制备方法
CN104592235A (zh) * 2014-12-26 2015-05-06 浙江永太科技股份有限公司 一种制备作为二肽基肽酶-4抑制剂的化合物的中间体
CN105073749A (zh) * 2012-12-17 2015-11-18 迈兰实验室有限公司 制备利拉利汀的改进方法
TWI508965B (zh) * 2008-12-23 2015-11-21 Boehringer Ingelheim Int 有機化合物的鹽形式
CN106188058A (zh) * 2015-05-29 2016-12-07 江苏天士力帝益药业有限公司 黄嘌呤衍生物
CN110590780A (zh) * 2019-10-29 2019-12-20 深圳市第二人民医院 治疗糖尿病的药物利拉利汀的制备方法
CN111187223A (zh) * 2020-03-09 2020-05-22 沧州那瑞化学科技有限公司 利拉利汀中间体2-氯甲基-4-甲基喹唑啉的合成方法

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1757606T1 (sl) * 2001-02-24 2009-10-31 Boehringer Ingelheim Pharma Ksantinski derivati za uporabo kot zdravila kot tudi postopek za njihovo pripravo
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7569574B2 (en) 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7482337B2 (en) * 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7566707B2 (en) 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10355304A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (de) 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7393847B2 (en) 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
US7179809B2 (en) * 2004-04-10 2007-02-20 Boehringer Ingelheim International Gmbh 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US7439370B2 (en) 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004043944A1 (de) 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
KR101452915B1 (ko) 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 다형태
EP1852108A1 (en) * 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
WO2008017670A1 (en) 2006-08-08 2008-02-14 Boehringer Ingelheim International Gmbh Pyrrolo [3, 2 -d] pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
WO2010018217A2 (en) 2008-08-15 2010-02-18 Boehringer Ingelheim International Gmbh Organic compounds for wound healing
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
CN102316875A (zh) 2009-02-13 2012-01-11 贝林格尔.英格海姆国际有限公司 用于治疗i型糖尿病、ii型糖尿病、葡萄糖耐量降低或高血糖症的sglt-2抑制剂
AU2010212823B2 (en) 2009-02-13 2016-01-28 Boehringer Ingelheim International Gmbh Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
UY32427A (es) 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
PT2395983T (pt) 2009-02-13 2020-07-03 Boehringer Ingelheim Int Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dp-iv e opcionalmente um agente antidiabético adicional e suas utilizações
JP2011057619A (ja) * 2009-09-10 2011-03-24 Tokai Univ 光学活性アミン化合物の製造方法、並びに、ジアステレオマー塩及びその製造方法
NZ598170A (en) 2009-10-02 2014-06-27 Boehringer Ingelheim Int Pharmaceutical compositions comprising bi-1356 and metformin
KR20120107080A (ko) 2009-11-27 2012-09-28 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
MX2012012438A (es) 2010-05-05 2012-11-29 Boehringer Ingelheim Int Formulaciones farmaceuticas que comprenden pioglitazona y linagliptina.
KR20220025926A (ko) 2010-06-24 2022-03-03 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
IT1403282B1 (it) * 2010-12-23 2013-10-17 Dipharma Francis Srl Procedimento per la preparazione di linagliptin
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
AU2012252380B2 (en) * 2011-05-10 2016-09-08 Sandoz Ag Polymorph of Linagliptin benzoate
WO2013074817A1 (en) 2011-11-16 2013-05-23 Assia Chemical Industries Ltd. Solid state forms of linagliptin
US9056112B2 (en) 2011-12-28 2015-06-16 Dr. Reddy's Laboratories Limited Process for preparation of pure linagliptin
US20130172244A1 (en) 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9879011B2 (en) 2012-03-12 2018-01-30 Cadila Healthcare Limited Amorphous form of linagliptin and process for preparation thereof
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP2854812A1 (en) 2012-05-24 2015-04-08 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada
WO2013174769A1 (en) 2012-05-25 2013-11-28 Boehringer Ingelheim International Gmbh Use of keratinocytes as a biologically active substance in the treatment of wounds, such as diabetic wounds, optionally in combination with a dpp-4 inhibitor
CN103319483B (zh) 2012-10-19 2016-08-03 药源药物化学（上海）有限公司 一种利拉列汀重要中间体的制备方法
CA2903577C (en) 2013-03-15 2023-10-17 Boehringer Ingelheim International Gmbh Use of linagliptin in cardio- and renoprotective antidiabetic therapy
HK1213818A1 (zh) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 依帕列净的治疗用途
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
ES2702174T3 (es) 2013-04-05 2019-02-27 Boehringer Ingelheim Int Usos terapéuticos de empagliflozina
DK2986304T3 (da) 2013-04-18 2022-04-04 Boehringer Ingelheim Int Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf.
US20160304520A1 (en) * 2013-07-11 2016-10-20 Wockhardt Limited An improved process for preparing Linagliptin and its key Intermediates
WO2015011609A1 (en) 2013-07-23 2015-01-29 Ranbaxy Laboratories Limited Process for the preparation of linagliptin and an intermediate thereof
ITMI20131836A1 (it) * 2013-11-06 2015-05-07 Chemelectiva S R L Processo ed intermedi per la preparazione di linagliptina
WO2015087240A1 (en) 2013-12-11 2015-06-18 Ranbaxy Laboratories Limited Process for the preparation of linagliptin and an intermediate thereof
WO2015107533A1 (en) * 2014-01-15 2015-07-23 Harman Finochem Limited A process for preparation of 1h-purine-2,6-dione, 8-[(3r)-3-amino-1-piperidinyl]-7 (2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2quinazolinyl) methyl] and its pharmaceutically acceptable salts
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
JPWO2015137496A1 (ja) 2014-03-14 2017-04-06 武田薬品工業株式会社 複素環化合物の製造法
CN104496989A (zh) * 2014-12-26 2015-04-08 寿光富康制药有限公司 一种利格列汀工业化制备工艺
CN104844602B (zh) * 2015-04-14 2018-07-20 威海迪素制药有限公司 一种利格列汀的制备方法
CN104892609B (zh) * 2015-04-23 2017-06-20 深圳市海滨制药有限公司 一种利拉利汀中间体及其制备方法和应用
JP6901976B2 (ja) * 2015-06-25 2021-07-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング キサンチンをベースとする化合物の調製方法
EP3156048A1 (en) 2015-10-13 2017-04-19 Galenicum Health S.L. Stable pharmaceutical composition of linagliptin in the form of immediate release tablets
MX390363B (es) 2016-06-10 2025-03-20 Boehringer Ingelheim Int Combinacion de linagliptina y metformina
CN109922813A (zh) 2016-11-10 2019-06-21 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途
US20180247672A1 (en) * 2017-02-24 2018-08-30 Entry Point Vr, Inc. Bundling Separate Video Files to Support a Controllable End-User Viewing Experience with Frame-Level Synchronization
IT201800005383A1 (it) 2018-05-15 2019-11-15 Intermedi e processi per la preparazione di linagliptin e suoi sali
HU231374B1 (hu) 2018-08-06 2023-04-28 Richter Gedeon Nyrt. Eljárás BOC-Linagliptin előállítására
EP4103157A1 (en) 2020-02-13 2022-12-21 Zaklady Farmaceutyczne Polpharma S.A. Pharmaceutical composition comprising linagliptin and metformin
CN112592320A (zh) * 2020-12-22 2021-04-02 江苏慧聚药业有限公司 一种利拉利汀中间体的有关物质及其合成方法
EP4482835A1 (en) 2022-02-21 2025-01-01 KRKA, D.D., Novo Mesto Process for purification of linagliptin

Family Cites Families (420)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2056046A (en) * 1933-05-19 1936-09-29 Rhone Poulenc Sa Manufacture of bases derived from benz-dioxane
US2375138A (en) * 1942-05-01 1945-05-01 American Cyanamid Co Alkamine esters of aryloxymethyl benzoic acid
US2629736A (en) * 1951-02-24 1953-02-24 Searle & Co Basically substituted n-alkyl derivatives of alpha, beta, beta-triarylpropionamides
US2730544A (en) * 1952-07-23 1956-01-10 Sahyun Lab Alkylaminoalkyl esters of hydroxycyclohexylbenzoic acid
US2750387A (en) * 1953-11-25 1956-06-12 Searle & Co Basically substituted derivatives of diarylaminobenzamides
DE1211359B (de) * 1955-11-29 1966-02-24 Oreal Oxydationsmittelfreies Kaltfaerbemittel fuer menschliches Haar
US2928833A (en) * 1959-03-03 1960-03-15 S E Massengill Company Theophylline derivatives
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US3454635A (en) * 1965-07-27 1969-07-08 Hoechst Ag Benzenesulfonyl-ureas and process for their manufacture
US3673241A (en) * 1968-04-04 1972-06-27 Ciba Geigy Corp Substituted benzaldehyde guanylhydrazones
ES385302A1 (es) 1970-10-22 1973-04-16 Miquel S A Lab Procedimiento para la obtencion de derivados trisubstitui- dos de etilendiamina.
DE2205815A1 (de) 1972-02-08 1973-08-16 Hoechst Ag Piperazinderivate und verfahren zu ihrer herstellung
JPS5512435B2 (zh) * 1972-07-01 1980-04-02
US4005208A (en) 1975-05-16 1977-01-25 Smithkline Corporation N-Heterocyclic-9-xanthenylamines
US4061753A (en) 1976-02-06 1977-12-06 Interx Research Corporation Treating psoriasis with transient pro-drug forms of xanthine derivatives
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
DE2758025A1 (de) 1977-12-24 1979-07-12 Bayer Ag Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung
DE2929596A1 (de) 1979-07-21 1981-02-05 Hoechst Ag Verfahren zur herstellung von oxoalkyl-xanthinen
CY1306A (en) 1980-10-01 1985-12-06 Glaxo Group Ltd Aminoalkyl furan derivative
US4382091A (en) 1981-04-30 1983-05-03 Syntex (U.S.A.) Inc. Stabilization of 1-substituted imidazole derivatives in talc
EP0109281A1 (en) 1982-11-15 1984-05-23 The Upjohn Company Compositions comprising flurbiprofen or ibuprofen
JPS6092912A (ja) 1983-10-27 1985-05-24 Nippon Denso Co Ltd 車高制御装置
FR2558162B1 (fr) 1984-01-17 1986-04-25 Adir Nouveaux derives de la xanthine, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
FI79107C (fi) * 1984-06-25 1989-11-10 Orion Yhtymae Oy Foerfarande foer framstaellning av stabil -form av prazosinhydroklorid.
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
GB8515934D0 (en) * 1985-06-24 1985-07-24 Janssen Pharmaceutica Nv (4-piperidinomethyl and-hetero)purines
US5258380A (en) * 1985-06-24 1993-11-02 Janssen Pharmaceutica N.V. (4-piperidinylmethyl and -hetero)purines
ES2058061T3 (es) 1985-10-25 1994-11-01 Beecham Group Plc Derivado de piperidina, su preparacion y su uso como medicamento.
US5433959A (en) 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
EP0237608B1 (de) 1986-03-21 1992-01-29 HEUMANN PHARMA GMBH & CO Kristalline, wasserfreie Sigma -Form von 2-[4-(2-Furoyl-(2-piperazin)-1-yl]-4-amino-6,7-dimethoxychinazolinhydrochlorid und Verfahren zu ihrer Herstellung
WO1987006941A1 (en) 1986-05-05 1987-11-19 The General Hospital Corporation Insulinotropic hormone
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
AU619444B2 (en) 1986-06-02 1992-01-30 Nippon Chemiphar Co. Ltd. 2-(2-aminobenzylsulfinyl)- benzimidazole derivatives
US4968672A (en) 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
JPS6440433A (en) 1987-08-05 1989-02-10 Green Cross Corp Aqueous liquid composition of thrombin
JPH0395177A (ja) 1988-05-19 1991-04-19 Chugai Pharmaceut Co Ltd 新規キノロンカルボン酸誘導体
US5329025A (en) * 1988-09-21 1994-07-12 G. D. Searle & Co. 3-azido compound
DE3926119A1 (de) 1989-08-08 1991-02-14 Bayer Ag 3-amino-5-aminocarbonyl-1,2,4-triazol-derivate
US5234897A (en) * 1989-03-15 1993-08-10 Bayer Aktiengesellschaft Herbicidal 3-amino-5-aminocarbonyl-1,2,4-triazoles
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
DE3916430A1 (de) * 1989-05-20 1990-11-22 Bayer Ag Verfahren zur herstellung von 3-amino-5-aminocarbonyl-1,2,4-triazol-derivaten
IL94390A (en) 1989-05-30 1996-03-31 Merck & Co Inc The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them
US5223499A (en) * 1989-05-30 1993-06-29 Merck & Co., Inc. 6-amino substituted imidazo[4,5-bipyridines as angiotensin II antagonists
US5332744A (en) * 1989-05-30 1994-07-26 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
HU208115B (en) 1989-10-03 1993-08-30 Biochemie Gmbh New process for producting pleuromutilin derivatives
FR2654935B1 (fr) 1989-11-28 1994-07-01 Lvmh Rech Utilisation de xanthines, eventuellement incorporees dans des liposomes, pour favoriser la pigmentation de la peau ou des cheveux.
PH30484A (en) 1990-02-19 1997-05-28 Ciba Geigy Acy compounds pharmaceutical composition containing said compound and method of use thereof
KR930000861B1 (ko) 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
ES2064887T3 (es) 1990-09-13 1995-02-01 Akzo Nobel Nv Composiciones quimicas solidas estabilizadas.
GB9020959D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
US5084460A (en) * 1990-12-24 1992-01-28 A. H. Robins Company, Incorporated Methods of therapeutic treatment with N-(3-ouinuclidinyl)-2-hydroxybenzamides and thiobenzamides
US5591762A (en) 1991-02-06 1997-01-07 Dr. Karl Thomae Gmbh Benzimidazoles useful as angiotensin-11 antagonists
US5594003A (en) 1991-02-06 1997-01-14 Dr. Karl Thomae Gmbh Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists
US5602127A (en) 1991-02-06 1997-02-11 Karl Thomae Gmbh (Alkanesultam-1-yl)-benzimidazol-1-yl)-1yl)-methyl-biphenyls useful as angiotensin-II antagonists
GB9109862D0 (en) 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
DE4124150A1 (de) 1991-07-20 1993-01-21 Bayer Ag Substituierte triazole
US5300298A (en) * 1992-05-06 1994-04-05 The Pennsylvania Research Corporation Methods of treating obesity with purine related compounds
GB9215633D0 (en) 1992-07-23 1992-09-09 Smithkline Beecham Plc Novel treatment
ATE165360T1 (de) * 1992-07-31 1998-05-15 Shionogi & Co Triazolylthiomethylthiocephalosporin- hydrochlorid, sein kristallines hydrat und seine herstellung
TW252044B (zh) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
DE4242459A1 (de) * 1992-12-16 1994-06-23 Merck Patent Gmbh Imidazopyridine
EP0638567A4 (en) 1993-02-18 1995-05-10 Kyowa Hakko Kogyo Kk ADENOSINE INHIBITORS.
JP3726291B2 (ja) 1993-07-05 2005-12-14 三菱ウェルファーマ株式会社 安定な結晶構造を有するベンゾオキサジン化合物およびその製造法
FR2707641B1 (fr) 1993-07-16 1995-08-25 Fournier Ind & Sante Composés de l'imidazol-5-carboxamide, leur procédé de préparation leurs intermédiaires et leur utilisation en thérapeutique.
DE4339868A1 (de) 1993-11-23 1995-05-24 Merck Patent Gmbh Imidazopyridazine
DE4404183A1 (de) * 1994-02-10 1995-08-17 Merck Patent Gmbh 4-Amino-1-piperidylbenzoylguanidine
US5545745A (en) 1994-05-23 1996-08-13 Sepracor, Inc. Enantioselective preparation of optically pure albuterol
CO4410190A1 (es) 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
ATE248153T1 (de) 1994-10-12 2003-09-15 Euro Celtique Sa Neue benzoxazole
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
US5821366A (en) 1995-05-19 1998-10-13 Chiroscience Limited Xanthines and their therapeutic use
JPH08333339A (ja) * 1995-06-08 1996-12-17 Fujisawa Pharmaceut Co Ltd 光学活性なピペリジン酢酸誘導体の製造法
GB9523752D0 (en) 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
DE19543478A1 (de) 1995-11-22 1997-05-28 Bayer Ag Kristallines Hydrochlorid von {(R)-(-)-2- N-[4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-buytl]-aminomethyl}-chroman
FR2742751B1 (fr) * 1995-12-22 1998-01-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
ES2174132T3 (es) 1995-12-26 2002-11-01 Alteon Inc N-acil-a,omp-alquil-hidrazino-carboximidamidas.
DE122010000020I1 (de) * 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
US5965555A (en) * 1996-06-07 1999-10-12 Hoechst Aktiengesellschaft Xanthine compounds having terminally animated alkynol side chains
WO1997046526A1 (en) 1996-06-07 1997-12-11 Eisai Co., Ltd. Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
US5958951A (en) * 1996-06-14 1999-09-28 Novo Nordiskials Modified form of the R(-)-N-(4,4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride
US5753635A (en) 1996-08-16 1998-05-19 Berlex Laboratories, Inc. Purine derivatives and their use as anti-coagulants
EA001881B1 (ru) 1996-09-23 2001-10-22 Эли Лилли Энд Компани Форма d дигидрата оланзапина
WO1998018770A1 (en) 1996-10-28 1998-05-07 Novo Nordisk A/S A process for the preparation of (-)-3,4-trans-diarylchromans
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
DE69732572T2 (de) 1996-11-12 2005-12-29 Novo Nordisk A/S Verwendung von glp-1 peptiden
GB9623859D0 (en) 1996-11-15 1997-01-08 Chiroscience Ltd Novel compounds
EA002754B1 (ru) 1996-12-24 2002-08-29 Байоджен, Инк. Устойчивые жидкие составы интерферона
DE19705233A1 (de) 1997-02-12 1998-08-13 Froelich Juergen C Verfahren zur Herstellung einer Formulierung enthaltend Arginin
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
TR199902233T2 (xx) 1997-03-13 1999-12-21 Hexal Ag Aside duyarl� benzimidazolerin amino asit/ siklodekstrin kombinasyonlar� ile stabilizasyonu.
US5972332A (en) 1997-04-16 1999-10-26 The Regents Of The University Of Michigan Wound treatment with keratinocytes on a solid support enclosed in a porous material
ZA984697B (en) 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
CN1284079A (zh) * 1997-12-05 2001-02-14 阿斯特拉曾尼卡英国有限公司 新化合物
ID21411A (id) 1997-12-10 1999-06-10 Takeda Chemical Industries Ltd Agen untuk mengobati daya tahan glukosa yang berisiko tinggi rusak
JPH11193270A (ja) * 1997-12-26 1999-07-21 Koei Chem Co Ltd 光学活性１−メチル−３−ピペリジンメタノールの製造方法
AU1688599A (en) 1998-01-05 1999-07-26 Eisai Co. Ltd. Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes
CA2819705C (en) 1998-02-02 2014-07-08 Trustees Of Tufts College Method of regulating glucose metabolism, and reagents related thereto
WO1999050248A1 (en) 1998-03-31 1999-10-07 Nissan Chemical Industries, Ltd. Pyridazinone hydrochloride compound and method for producing the same
CA2268621A1 (en) 1998-04-13 1999-10-13 Takeda Chemical Industries, Ltd. 2-pipirazinone-1-acetic acid derivative, production and use thereof
US6207207B1 (en) 1998-05-01 2001-03-27 Mars, Incorporated Coated confectionery having a crispy starch based center and method of preparation
DE19823831A1 (de) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
CN1185013C (zh) 1998-07-15 2005-01-19 旭化成株式会社 赋形剂
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
IT1312018B1 (it) * 1999-03-19 2002-04-04 Fassi Aldo Procedimento migliorato per la produzione di sali non igroscopicidella l(-)-carnitina.
AU4431000A (en) 1999-05-12 2000-12-05 Fujisawa Pharmaceutical Co., Ltd. Novel use
US20040152659A1 (en) 1999-05-12 2004-08-05 Fujisawa Pharmaceutical Co. Ltd. Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
WO2000072799A2 (en) 1999-05-27 2000-12-07 The University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
MEP45508A (en) 1999-06-21 2011-02-10 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof
US6448323B1 (en) 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
ES2166270B1 (es) 1999-07-27 2003-04-01 Almirall Prodesfarma Sa Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
GB9928330D0 (en) 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
NZ531929A (en) 1999-12-23 2006-01-27 Novartis Ag Use of nateglinide as a hypoglycemic agent for treating impaired glucose metabolism
CA2396079A1 (en) 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US6362172B2 (en) 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
DK1741446T3 (da) 2000-01-21 2008-06-02 Novartis Pharma Ag Kombinationer indeholdende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
JP4621326B2 (ja) 2000-02-01 2011-01-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 テプレノンの安定化組成物
CA2369076A1 (en) * 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
AU2001234114A1 (en) 2000-02-24 2001-09-03 Takeda Chemical Industries Ltd. Drugs containing combined active ingredients
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
JP2001278812A (ja) 2000-03-27 2001-10-10 Kyoto Pharmaceutical Industries Ltd 錠剤用崩壊剤及びこれを用いた錠剤
ES2525041T3 (es) 2000-03-31 2014-12-16 Royalty Pharma Collection Trust Método para la mejora de la señalización de islotes en diabetes mellitus y para su prevención
JP2001292388A (ja) 2000-04-05 2001-10-19 Sharp Corp 再生装置
GB0008694D0 (en) 2000-04-07 2000-05-31 Novartis Ag Organic compounds
US6962998B2 (en) 2000-06-14 2005-11-08 Toray Industries, Inc. Processes for producing racemic piperidine derivative and for producing optically active piperidine derivative
JP2002193933A (ja) * 2000-06-14 2002-07-10 Toray Ind Inc 光学活性ピペリジン誘導体またはその酸塩の製造方法
US7078397B2 (en) 2000-06-19 2006-07-18 Smithkline Beecham Corporation Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
JP2004502690A (ja) 2000-07-04 2004-01-29 ノボ　ノルディスク　アクティーゼルスカブ 酵素ｄｐｐ−ｉｖのインヒビターである複素環式化合物
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
PT1308439E (pt) * 2000-08-10 2008-12-12 Mitsubishi Tanabe Pharma Corp Derivados de prolina e sua utilização como fármacos
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
US20060034922A1 (en) 2000-11-03 2006-02-16 Andrx Labs, Llc Controlled release metformin compositions
WO2002051836A1 (en) 2000-12-27 2002-07-04 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
FR2819254B1 (fr) 2001-01-08 2003-04-18 Fournier Lab Sa Nouveaux composes de la n-(phenylsulfonyl) glycine, leur procede de preparation et leur utilisation pour obtenir des compostions pharmaceutiques
DE10109021A1 (de) 2001-02-24 2002-09-05 Boehringer Ingelheim Pharma Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10117803A1 (de) 2001-04-10 2002-10-24 Boehringer Ingelheim Pharma Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
IL157179A0 (en) 2001-02-02 2004-02-08 Takeda Chemical Industries Ltd Fused heterocyclic compounds
WO2002066015A1 (en) 2001-02-16 2002-08-29 Bristol-Myers Squibb Pharma Company Use of polyalkylamine polymers in controlled release devices
SI1757606T1 (sl) 2001-02-24 2009-10-31 Boehringer Ingelheim Pharma Ksantinski derivati za uporabo kot zdravila kot tudi postopek za njihovo pripravo
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6693094B2 (en) 2001-03-22 2004-02-17 Chrono Rx Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
JP2002348279A (ja) 2001-05-25 2002-12-04 Nippon Kayaku Co Ltd 光学活性ピリジルケトン誘導体の製造方法並びに光学活性ピリジルケトン誘導体
DE10130371A1 (de) 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
GB0115517D0 (en) 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
WO2003002553A2 (en) 2001-06-27 2003-01-09 Smithkline Beecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
ATE374181T1 (de) 2001-06-27 2007-10-15 Smithkline Beecham Corp Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren
US6869947B2 (en) * 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
JP2005502624A (ja) 2001-07-03 2005-01-27 ノボ　ノルディスク　アクティーゼルスカブ 糖尿病を治療するための、ｄｐｐ−ｉｖを阻害するプリン誘導体
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
EP1463727A2 (en) 2001-09-19 2004-10-06 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
DE50213462D1 (de) 2001-10-15 2009-05-28 Hemoteq Ag Beschichtung von stents zur verhinderung von restenose
DE10151296A1 (de) 2001-10-17 2003-04-30 Boehringer Ingelheim Pharma Keratinozyten verwendbar als biologisch aktive Substanz bei der Behandlung von Wunden
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US6861440B2 (en) 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
US20030083354A1 (en) 2001-10-26 2003-05-01 Pediamed Pharmaceuticals, Inc. Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions
CA2363053C (en) 2001-11-09 2011-01-25 Bernard Charles Sherman Clopidogrel bisulfate tablet formulation
JP2003342259A (ja) * 2001-12-21 2003-12-03 Toray Ind Inc 光学活性シスピペリジン誘導体の製造法
KR20040064687A (ko) 2001-12-21 2004-07-19 도오레 화인케미칼 가부시키가이샤 광학 활성 시스 피페리딘 유도체의 제조법
US6727261B2 (en) 2001-12-27 2004-04-27 Hoffman-La Roche Inc. Pyrido[2,1-A]Isoquinoline derivatives
AU2003201274A1 (en) * 2002-01-11 2003-07-24 Novo Nordisk A/S Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes
ES2298351T5 (es) 2002-01-16 2012-01-26 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Método para producir un comprimido farmacéutico de dos capas que comprenden telmisartán e hidroclorotiazida.
EP1333033A1 (en) 2002-01-30 2003-08-06 Boehringer Ingelheim Pharma GmbH & Co.KG FAP-activated anti-tumor compounds
PL373914A1 (en) 2002-02-01 2005-09-19 Pfizer Products Inc. Immediate release dosage forms containing solid drug dispersions
US7610153B2 (en) 2002-02-13 2009-10-27 Virginia Commonwealth University Multi-drug titration and evaluation
MXPA04008164A (es) 2002-02-21 2005-05-17 Biovail Lab Inc Formas de dosificacion de liberacion controlada.
US7074798B2 (en) * 2002-02-25 2006-07-11 Eisai Co., Ltd Xanthine derivative and DPPIV inhibitor
HUP0200849A2 (hu) 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
JP4298212B2 (ja) 2002-03-29 2009-07-15 大日本印刷株式会社 塩酸エピナスチン高融点型結晶の製造法
JP2003300977A (ja) 2002-04-10 2003-10-21 Sumitomo Pharmaceut Co Ltd キサンチン誘導体
JP2005528400A (ja) 2002-04-16 2005-09-22 メルク　エンド　カムパニー　インコーポレーテッド チロシンキナーゼ活性を有する塩の固体形態
JP4424203B2 (ja) 2002-04-26 2010-03-03 味の素株式会社 糖尿病予防・治療剤
WO2003094909A2 (en) 2002-05-09 2003-11-20 Enos Pharmaceuticals, Inc. Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
GB0212412D0 (en) 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
ES2270047T3 (es) * 2002-05-31 2007-04-01 Schering Corporation Proceso para preparar inhibidores de la fosfodiesterasa v de xantina y sus precursores.
EP1514552A4 (en) * 2002-06-06 2008-04-02 Eisai R&D Man Co Ltd NEW MILED IMIDAZOLE DERIVATIVE
FR2840897B1 (fr) 2002-06-14 2004-09-10 Fournier Lab Sa Nouveaux derives d'arylsulfonamides et leur utilisation en therapeutique
US20040002615A1 (en) * 2002-06-28 2004-01-01 Allen David Robert Preparation of chiral amino-nitriles
US20040023981A1 (en) 2002-07-24 2004-02-05 Yu Ren Salt forms with tyrosine kinase activity
AR040661A1 (es) 2002-07-26 2005-04-13 Theravance Inc Diclorhidrato cristalino de n-{2-[-((r)-2-hidroxi-2-feniletilamino)fenil]etil}-(r)-2hidroxi-2-(3-formamido-4-hidroxifenil)etilamina, agonista del receptor adrenergico beta 2
TW200404796A (en) 2002-08-19 2004-04-01 Ono Pharmaceutical Co Nitrogen-containing compound
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE10238243A1 (de) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EA016166B1 (ru) 2002-08-21 2012-02-28 Бёрингер Ингельхайм Фарма Гмбх & Ко. Кг 8-[3-аминопиперидин-1-ил]ксантины, способ их получения и их применение в качестве лекарственных средств
US7495005B2 (en) 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
DE10238470A1 (de) 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7569574B2 (en) * 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10238477A1 (de) 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
EP1537880A4 (en) 2002-09-11 2009-07-01 Takeda Pharmaceutical Sustained release preparation
BR0314356A (pt) 2002-09-16 2005-07-19 Wyeth Corp Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas
US20060094722A1 (en) * 2002-09-26 2006-05-04 Eisai Co., Ltd. Combination drug
WO2004033455A2 (en) 2002-10-08 2004-04-22 Novo Nordisk A/S Hemisuccinate salts of heterocyclic dpp-iv inhibitors
CN1720025A (zh) 2002-10-08 2006-01-11 兰贝克赛实验室有限公司 加巴喷丁片剂及其制备
US20040122048A1 (en) 2002-10-11 2004-06-24 Wyeth Holdings Corporation Stabilized pharmaceutical composition containing basic excipients
US6861526B2 (en) * 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
AU2003298596B2 (en) 2002-10-18 2008-12-18 Merck Sharp & Dohme Corp. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JP2004161749A (ja) * 2002-10-24 2004-06-10 Toray Fine Chemicals Co Ltd 光学活性含窒素化合物の製造方法
AU2003280680A1 (en) 2002-11-01 2004-06-18 Sumitomo Pharmaceuticals Co., Ltd. Xanthine compound
BR0315796A (pt) 2002-11-07 2005-09-13 Merck & Co Inc Composto, composição farmacêutica, e, métodos para tratar diabetes, para tratar hiperglicemia, e para tratar obesidade em um mamìfero
US7482337B2 (en) * 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10251927A1 (de) 2002-11-08 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10254304A1 (de) * 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
UY28103A1 (es) 2002-12-03 2004-06-30 Boehringer Ingelheim Pharma Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
US7109192B2 (en) * 2002-12-03 2006-09-19 Boehringer Ingelheim Pharma Gmbh & Co Kg Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
WO2004052362A1 (en) 2002-12-10 2004-06-24 Novartis Ag Combination of an dpp-iv inhibitor and a ppar-alpha compound
UA83813C2 (ru) 2002-12-20 2008-08-26 Бёрингер Ингельхайм Фарма Гмбх & Ко. Кг Порошковое лекарственное средство, которое содержит соль тиотропия и ксинафоат салметерола
US20040152720A1 (en) 2002-12-20 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powdered medicaments containing a tiotropium salt and salmeterol xinafoate
SI1599222T1 (sl) 2003-01-08 2009-08-31 Novartis Vaccines & Diagnostic Stabilizirani vodni sestavki, ki obsegajo inhibitor poti tkivnega faktorja (TFPI) ali varianto inhibitorja poti tkivnega faktorja
ES2295816T3 (es) 2003-01-14 2008-04-16 Arena Pharmaceuticals, Inc. Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia.
DE10335027A1 (de) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP2004250336A (ja) 2003-02-18 2004-09-09 Kao Corp コーティング錠及び糖衣錠の製造法
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7442387B2 (en) 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
JP2006519852A (ja) 2003-03-12 2006-08-31 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ 弱塩基の塩
BRPI0408490A (pt) 2003-03-18 2006-04-04 Novartis Ag composições que compreendem ácidos graxos e aminoácidos
JPWO2004096806A1 (ja) 2003-04-30 2006-07-13 大日本住友製薬株式会社 縮合イミダゾール誘導体
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
TW200510277A (en) 2003-05-27 2005-03-16 Theravance Inc Crystalline form of β2-adrenergic receptor agonist
AU2003902828A0 (en) 2003-06-05 2003-06-26 Fujisawa Pharmaceutical Co., Ltd. Dpp-iv inhibitor
DE10327439A1 (de) 2003-06-18 2005-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7566707B2 (en) * 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
BRPI0411509A (pt) 2003-06-20 2006-07-25 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e sua utilização
MXPA05013904A (es) 2003-06-20 2006-02-24 Hoffmann La Roche Derivados de pirido[2,1-a] isoquinolinas como inhibidores de dipeptidil-peptidasa iv(dpp-iv).
JO2625B1 (en) 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salts of dipeptidyl betidase inhibitor 4
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
US7132426B2 (en) 2003-07-14 2006-11-07 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20050027012A1 (en) 2003-07-16 2005-02-03 Boehringer Ingelheim International Gmbh Tablets containing ambroxol
CA2536111A1 (en) 2003-07-24 2005-02-03 Wockhardt Limited Oral compositions for treatment of diseases
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
CA2534649A1 (en) 2003-08-01 2005-02-10 Genelabs Technologies, Inc. Bicyclic imidazol derivatives against flaviviridae
CN101856348A (zh) 2003-08-29 2010-10-13 斯隆-凯特林癌症研究所 联合治疗癌症的方法
JP2007505121A (ja) 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
ATE534404T1 (de) 2003-10-03 2011-12-15 Takeda Pharmaceutical Dipeptidylpeptidase-iv-inhibitoren zur behandlung von diabetes-patienten mit sekundärversagen durch sulfonylharnstoffe
BR0304443B1 (pt) 2003-10-28 2012-08-21 processo para obtenção de concentrados de titánio com elevado teor de tio2 e baixo teor de radionuclìdeos a partir de concentrados mecánicos de anatásio.
US7107714B2 (en) 2003-11-10 2006-09-19 Marketing Displays, Inc. Portable snap-fit sign stand
KR20130105741A (ko) 2003-11-17 2013-09-25 노파르티스 아게 디펩티딜 펩티다제 ⅳ 억제제의 용도
DE10355304A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
WO2005053695A1 (ja) * 2003-12-04 2005-06-16 Eisai Co., Ltd. 多発性硬化症予防剤または治療剤
US7217711B2 (en) * 2003-12-17 2007-05-15 Boehringer Ingelheim International Gmbh Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions
DE10359098A1 (de) 2003-12-17 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-(Piperazin-1-yl)- und 2-([1,4]Diazepan-1-yl)-imidazo[4,5-d]pyridazin-4-one, deren Herstellung und deren Verwendung als Arzneimittel
BRPI0417668A (pt) * 2003-12-18 2007-04-03 Tibotec Pharm Ltd derivados de piperidina-amino-benzimidazol como inibidores de replicação do vìrus sincicial respiratório
DE10360835A1 (de) 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
AU2004303604B2 (en) 2003-12-24 2011-03-24 Prosidion Limited Heterocyclic derivatives as GPCR receptor agonists
JP4994043B2 (ja) 2004-01-21 2012-08-08 エランコ・アニマル・ヘルス・アイルランド・リミテッド ミトラタピデ経口用溶液
JP4733058B2 (ja) * 2004-02-18 2011-07-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ８−［３−アミノ−ピペリジン−１−イル］−キサンチン、その製造及びそのｄｐｐ−ｉｖインヒビターの形態での使用
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004019540A1 (de) 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen
DE102004009039A1 (de) * 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
EP1593671A1 (en) 2004-03-05 2005-11-09 Graffinity Pharmaceuticals AG DPP-IV inhibitors
US7393847B2 (en) * 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
GEP20094679B (en) 2004-03-15 2009-05-10 Takeda Pharmaceuticals Co Dipeptidyl peptidase inhibitors
JP4181605B2 (ja) 2004-03-16 2008-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換フェニル誘導体、該化合物を含有する医薬品及びその使用と製造方法
EP1577306A1 (de) 2004-03-17 2005-09-21 Boehringer Ingelheim Pharma GmbH & Co.KG Neue Benzoxazinonderivate als langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
US7179809B2 (en) * 2004-04-10 2007-02-20 Boehringer Ingelheim International Gmbh 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
CA2561210A1 (en) 2004-04-10 2005-10-20 Boehringer Ingelheim International Gmbh Novel 2-amino-imidazo[4,5-d]pyridazin-4-ones and 2-amino-imidazo[4,5-c]pyridin-4-ones, production and use thereof as medicaments
US20050239778A1 (en) 2004-04-22 2005-10-27 Boehringer Ingelheim International Gmbh Novel medicament combinations for the treatment of respiratory diseases
US20050244502A1 (en) 2004-04-28 2005-11-03 Mathias Neil R Composition for enhancing absorption of a drug and method
US7439370B2 (en) * 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
CA2566108C (en) 2004-05-12 2010-04-06 Pfizer Products Inc. Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
DE102004024454A1 (de) 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
PE20060315A1 (es) 2004-05-24 2006-05-15 Irm Llc Compuestos de tiazol como moduladores de ppar
TWI354569B (en) 2004-05-28 2011-12-21 Bristol Myers Squibb Co Coated tablet formulation and method
CA2567309A1 (en) 2004-06-01 2005-12-15 Ares Trading S.A. Method of stabilizing proteins
US7935723B2 (en) 2004-06-04 2011-05-03 Novartis Pharma Ag Use of organic compounds
WO2005120576A2 (en) 2004-06-09 2005-12-22 Yasoo Health Composition and method for improving pancreatic islet cell survival
DE102004030502A1 (de) * 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
CA2573209A1 (en) 2004-07-14 2006-01-19 Novartis Ag Combination of dpp-iv inhibitors and compounds modulating 5-ht3 and/or 5-ht4 receptors
JP2006045156A (ja) * 2004-08-06 2006-02-16 Sumitomo Pharmaceut Co Ltd 縮合ピラゾール誘導体
TW200613275A (en) 2004-08-24 2006-05-01 Recordati Ireland Ltd Lercanidipine salts
US20070259927A1 (en) 2004-08-26 2007-11-08 Takeda Pharmaceutical Company Limited Remedy for Diabetes
DE102004043944A1 (de) * 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
CN1759834B (zh) 2004-09-17 2010-06-23 中国医学科学院医药生物技术研究所 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
AU2005289881A1 (en) 2004-09-23 2006-04-06 Amgen Inc. Substituted sulfonamidopropionamides and methods of use
CA2580266A1 (en) 2004-10-08 2006-04-20 Novartis Ag Combination of organic compounds
KR20070073887A (ko) 2004-10-12 2007-07-10 그렌마크 파머수티칼스 에스. 아. 신규한 디펩티딜 펩티다제 ⅳ 억제제, 이를 함유하는약제학적 조성물, 및 이의 제조공정
US20090253752A1 (en) 2004-10-25 2009-10-08 Bryan Burkey Combination of dpp-iv inhibitor, ppar antidiabetic and metmorfin
DE102005013967A1 (de) 2004-11-05 2006-10-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Bradykinin-B1-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
CN101103032B (zh) 2004-12-24 2011-05-11 大日本住友制药株式会社 双环吡咯衍生物
KR100760430B1 (ko) 2004-12-31 2007-10-04 한미약품 주식회사 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
GT200600008A (es) 2005-01-18 2006-08-09 Formulacion de compresion directa y proceso
EP1874339A1 (en) 2005-04-21 2008-01-09 Gastrotech Pharma A/S Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
ES2477868T3 (es) 2005-04-22 2014-07-18 Alantos Pharmaceuticals Holding, Inc. Inhibidores de dipeptidil peptidasa-IV
US7898255B2 (en) 2005-04-25 2011-03-01 Hitachi, Ltd. Inspection apparatus using magnetic resonance and nuclear magnetic resonance signal receiver coil
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
CN101203494A (zh) 2005-05-25 2008-06-18 惠氏公司 合成经取代3-氰基喹啉和其中间物的方法
GT200600218A (es) 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
US7585630B2 (en) 2005-06-20 2009-09-08 Decode Genetics Ehf. Genetic variants in the TCF7L2 gene as diagnostic markers for risk of type 2 diabetes mellitus
EP1904531B1 (en) 2005-07-08 2010-10-06 Pfizer Limited Madcam antibodies
UY29694A1 (es) 2005-07-28 2007-02-28 Boehringer Ingelheim Int Metodos para prevenir y tratar trastornos metabolicos y nuevos derivados de pirazol-o-glucosido
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
KR20080030652A (ko) 2005-08-11 2008-04-04 에프. 호프만-라 로슈 아게 Ｄｐｐ-ｉｖ 억제제를 포함하는 약학 조성물
EP1760076A1 (en) 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
ME02005B (me) 2005-09-14 2012-08-31 Takeda Pharmaceuticals Co Inhibitori dipeptidil peptidaze za lečenje dijabetesa
DE602006006461D1 (de) 2005-09-16 2009-06-04 Arena Pharm Inc Stoffwechselmodulatoren und behandlung damit verbundener erkrankungen
JP5072848B2 (ja) 2005-09-20 2012-11-14 ノバルティス アーゲー 低血糖イベントを低減するためのｄｐｐ−ｉｖ阻害剤の使用
JOP20180109A1 (ar) 2005-09-29 2019-01-30 Novartis Ag تركيبة جديدة
AU2006306420A1 (en) 2005-10-25 2007-05-03 Merck Sharp & Dohme Corp. Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension
JP2009515005A (ja) 2005-11-04 2009-04-09 エルエス ケーブル リミテッド 水酸化マグネシウムポリマーハイブリッド粒子の製造方法
EP1962827A4 (en) 2005-12-16 2011-02-16 Merck Sharp & Dohme PHARMACEUTICAL COMPOSITIONS OF COMBINATIONS OF DIPEPTIDYL-PEPTIDASE-4-INHIBITORS WITH METFORMIN
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
CA2633484A1 (en) 2005-12-23 2007-06-28 Novartis Ag Condensed heterocyclic compounds useful as dpp-iv inhibitors
US20090054512A1 (en) 2006-01-06 2009-02-26 Foley James E Use of organic compounds
US7745414B2 (en) 2006-02-15 2010-06-29 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
WO2007099345A1 (en) 2006-03-02 2007-09-07 Betagenon Ab Medical use of bmp-2 and/ or bmp-4
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
US8455435B2 (en) 2006-04-19 2013-06-04 Ludwig-Maximilians-Universitat Munchen Remedies for ischemia
KR101452915B1 (ko) 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 다형태
EP1852108A1 (en) * 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
PT2020996E (pt) 2006-05-16 2012-02-20 Gilead Sciences Inc Método e composições para tratar neoplasias malignas hematológicas
KR20070111099A (ko) 2006-05-16 2007-11-21 영진약품공업주식회사 시타글립틴 염산염의 신규 결정형, 이의 제조 방법과 이를포함하는 약학적 조성물
US20080064717A1 (en) 2006-05-19 2008-03-13 Rajesh Iyengar Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
KR100858848B1 (ko) 2006-05-23 2008-09-17 한올제약주식회사 메트포르민 서방정
WO2007149797A2 (en) 2006-06-19 2007-12-27 Novartis Ag Use of organic compounds
WO2007148185A2 (en) 2006-06-21 2007-12-27 Pfizer Products Inc. Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
AT503443B1 (de) 2006-06-23 2007-10-15 Leopold Franzens Uni Innsbruck Verfahren zur herstellung einer eisfläche für eissportbahnen
TW200811147A (en) 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
TW200811140A (en) 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
WO2008017670A1 (en) 2006-08-08 2008-02-14 Boehringer Ingelheim International Gmbh Pyrrolo [3, 2 -d] pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
US8039441B2 (en) 2006-08-15 2011-10-18 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture
JP2010501010A (ja) 2006-08-17 2010-01-14 ウェルスタット セラピューティクス コーポレイション 代謝障害のための併用処置
DE102006042586B4 (de) 2006-09-11 2014-01-16 Betanie B.V. International Trading Verfahren zum mikropartikulären Beladen von hochpolymeren Kohlenhydraten mit hydrophoben Wirkflüssigkeiten
US7879806B2 (en) 2006-11-06 2011-02-01 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzonitrile derivates, medicaments containing such compounds, their use and process for their manufacture
US7956201B2 (en) 2006-11-06 2011-06-07 Hoffman-La Roche Inc. Process for the preparation of (S)-4-fluoromethyl-dihydro-furan-2-one
AR063627A1 (es) 2006-11-09 2009-02-04 Boehringer Ingelheim Int Terapia combinada con inhibidores de sgl t-2 y sus composiciones farmaceuticas
JP5330260B2 (ja) 2006-12-06 2013-10-30 スミスクライン ビーチャム コーポレーション 二環式化合物ならびに抗糖尿病薬としての使用
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
CL2008000017A1 (es) 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
CL2008000133A1 (es) 2007-01-19 2008-05-23 Boehringer Ingelheim Int Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido combinado con al menos un segundo agente terapeutico; y uso de la composicion para el tratamiento de diabetes mellitus, cataratas, neuropatia, infarto de miocardio, e
EA015180B1 (ru) 2007-02-01 2011-06-30 Такеда Фармасьютикал Компани Лимитед Твердый препарат, содержащий алоглиптин и пиоглитазон
PE20081734A1 (es) 2007-02-01 2009-01-19 Takeda Pharmaceutical Comprimido que comprende 2-[[6-[(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo y celulosa microcristalina
WO2008113000A1 (en) 2007-03-15 2008-09-18 Nectid, Inc. Anti-diabetic combinations comprising a slow release biguanide composition and an immediate release dipeptidyl peptidase iv inhibitor composition
EP2143443B1 (en) 2007-04-03 2014-11-19 Mitsubishi Tanabe Pharma Corporation A combination of dipeptidyl peptidase iv inhibitor and sweetener for use in the treatment of obesity
WO2008130998A2 (en) 2007-04-16 2008-10-30 Smith & Nephew, Inc. Powered surgical system
PE20090696A1 (es) 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
ES2388967T3 (es) 2007-05-04 2012-10-22 Bristol-Myers Squibb Company Agonistas [6,6]- y [6,7]-bicíclicos del receptor GPR119 acoplado a la proteína G
ES2398478T5 (es) 2007-07-09 2016-02-25 Symrise Ag Sales solubles estables de ácido fenilbencimidazolsulfónico de pH 6,0 a menos de 6,8
CN101801351B (zh) 2007-07-19 2012-12-12 武田药品工业株式会社 包含阿格列汀和盐酸二甲双胍的固体制剂
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
PE20090987A1 (es) 2007-08-16 2009-08-14 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de pirazol-o-glucosido
UY31291A1 (es) 2007-08-16 2009-03-31 Composicion farmacéutica que comprende un derivado de pirazol-0-glucosido
PE20090603A1 (es) 2007-08-16 2009-06-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv
NZ600126A (en) 2007-08-17 2013-12-20 Boehringer Ingelheim Int Purine derivatives for use in the treatment of fap-related diseases
US8338450B2 (en) 2007-09-21 2012-12-25 Lupin Limited Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors
MX2010005245A (es) 2007-11-16 2010-06-01 Novo Nordisk As Composiciones farmaceuticas que comprenden peptidos glp-1 o exendin-4 y un peptido de insulina basal.
CN101234105A (zh) 2008-01-09 2008-08-06 北京润德康医药技术有限公司 一种含有二甲双胍和维格列汀的药用组合物及其制备方法
US20090186086A1 (en) 2008-01-17 2009-07-23 Par Pharmaceutical, Inc. Solid multilayer oral dosage forms
TW200936136A (en) 2008-01-28 2009-09-01 Sanofi Aventis Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic application
AU2009210641A1 (en) 2008-02-05 2009-08-13 Merck Sharp & Dohme Corp. Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-IV inhibitor
EP2259676A4 (en) 2008-03-04 2011-03-16 Merck Sharp & Dohme PHARMACEUTICAL COMPOSITIONS OF A COMBINATION OF METFORMIN AND A DIPEPTIDYL PEPTIDASE IV HEMMER
EA019752B1 (ru) 2008-03-05 2014-06-30 Такеда Фармасьютикал Компани Лимитед Гетероциклическое амидное соединение и его применение для лечения/профилактики диабета
US8551524B2 (en) 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
BRPI0909469A2 (pt) 2008-03-31 2015-12-29 Metabolex Inc compostos de oximetileno de arila e usos dos mesmos
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
WO2010018217A2 (en) 2008-08-15 2010-02-18 Boehringer Ingelheim International Gmbh Organic compounds for wound healing
JP2010053576A (ja) 2008-08-27 2010-03-11 Sumitomo Forestry Co Ltd 舗装用マット
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
UY32177A (es) 2008-10-16 2010-05-31 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
WO2010045656A2 (en) 2008-10-17 2010-04-22 Nectid, Inc. Novel sglt2 inhibitor dosage forms
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
AU2010212823B2 (en) 2009-02-13 2016-01-28 Boehringer Ingelheim International Gmbh Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
PT2395983T (pt) 2009-02-13 2020-07-03 Boehringer Ingelheim Int Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dp-iv e opcionalmente um agente antidiabético adicional e suas utilizações
UY32427A (es) 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
TW201031661A (en) 2009-02-17 2010-09-01 Targacept Inc Fused benzazepines as neuronal nicotinic acetylcholine receptor ligands
JP2012520868A (ja) 2009-03-20 2012-09-10 ファイザー・インク ３−オキサ−７−アザビシクロ［３．３．１］ノナン
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
WO2010140111A1 (en) 2009-06-02 2010-12-09 Ranbaxy Laboratories Limited Pharmaceutical compositions containing a combination of an antihistamine and a decongestant
JP2012530135A (ja) 2009-06-15 2012-11-29 メルク・シャープ・エンド・ドーム・コーポレイション ジペプチジルペプチダーゼ−４阻害剤及びピオグリタゾンの併用医薬組成物
BR112012001372A2 (pt) 2009-07-21 2016-12-27 Keryx Biopharmaceuticals Inc comprimido, e, métodos para preparar um comprimido e para a profilaxia ou tratamento de hiperfosfatemia.
UY32919A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
NZ598170A (en) 2009-10-02 2014-06-27 Boehringer Ingelheim Int Pharmaceutical compositions comprising bi-1356 and metformin
KR20120107080A (ko) 2009-11-27 2012-09-28 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
JP2010070576A (ja) 2009-12-28 2010-04-02 Sato Pharmaceutical Co Ltd 速溶解性錠剤
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
MX2012012438A (es) 2010-05-05 2012-11-29 Boehringer Ingelheim Int Formulaciones farmaceuticas que comprenden pioglitazona y linagliptina.
CN103037849A (zh) 2010-06-22 2013-04-10 安成国际药业股份有限公司 具有减少的食物效应的控释组合物
KR20220025926A (ko) 2010-06-24 2022-03-03 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AU2011295837B2 (en) 2010-09-03 2015-06-18 Astrazeneca Uk Limited Drug formulations using water soluble antioxidants
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
WO2012088682A1 (en) 2010-12-29 2012-07-05 Shanghai Fochon Pharmaceutical Co Ltd. 2-(3-aminopiperidin-1-yl)-[1,2,4]triazolo[1,5-c]pyrimidine-5,7(3h,6h)-dione derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
BR112013019026A2 (pt) 2011-02-01 2016-10-04 Astrazeneca Uk Ltd formulações farmacêuticas incluindo um composto amina
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
AU2012252380B2 (en) 2011-05-10 2016-09-08 Sandoz Ag Polymorph of Linagliptin benzoate
CN103781788B (zh) 2011-07-15 2016-08-17 勃林格殷格翰国际有限公司 经取代的喹唑啉、其制备及其在药物组合物中的用途
US20130172244A1 (en) 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
EP2800803A1 (en) 2012-01-04 2014-11-12 The Procter and Gamble Company Active containing fibrous structures with multiple regions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP2854812A1 (en) 2012-05-24 2015-04-08 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada
WO2013174769A1 (en) 2012-05-25 2013-11-28 Boehringer Ingelheim International Gmbh Use of keratinocytes as a biologically active substance in the treatment of wounds, such as diabetic wounds, optionally in combination with a dpp-4 inhibitor
WO2013179307A2 (en) 2012-05-29 2013-12-05 Mylan Laboratories Limited Stabilized pharmaceutical compositions of saxagliptin
EP2908806A1 (en) 2012-10-09 2015-08-26 Boehringer Ingelheim International GmbH Use of selectively moisture-adjusted tabletting material in the production of mechanically stable tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing tablets
US20140100292A1 (en) 2012-10-09 2014-04-10 Boehringer Ingelheim International Gmbh Use of moisture-conditioned disintegrants or expanding agents in tablet manufacture for the selective adjustment of the mechanical properties, the dissolving kinetics and/or the water loading of the tablets
CA2903577C (en) 2013-03-15 2023-10-17 Boehringer Ingelheim International Gmbh Use of linagliptin in cardio- and renoprotective antidiabetic therapy
JP2016518438A (ja) 2013-05-17 2016-06-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＤＰＰ−４阻害薬とα−グルコシダーゼ阻害薬との組合せ
CN105283187A (zh) 2013-06-14 2016-01-27 勃林格殷格翰国际有限公司 用于治疗糖尿病及其并发症的二肽基肽酶-4抑制剂
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
US20160106677A1 (en) 2014-10-17 2016-04-21 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107011345A (zh) * 2008-12-23 2017-08-04 勃林格殷格翰国际有限公司 有机化合物的盐形式
TWI508965B (zh) * 2008-12-23 2015-11-21 Boehringer Ingelheim Int 有機化合物的鹽形式
CN103781788A (zh) * 2011-07-15 2014-05-07 勃林格殷格翰国际有限公司 经取代的喹唑啉、其制备及其在药物组合物中的用途
CN103781788B (zh) * 2011-07-15 2016-08-17 勃林格殷格翰国际有限公司 经取代的喹唑啉、其制备及其在药物组合物中的用途
CN102372691A (zh) * 2011-11-15 2012-03-14 海门慧聚药业有限公司 (r)-3-苯二甲酰亚胺哌啶酒石酸盐的制备工艺
CN102516225A (zh) * 2011-11-18 2012-06-27 海门慧聚药业有限公司 新型医药中间体(r)-3-苯二甲酰亚胺哌啶盐酸盐的合成
CN103450201A (zh) * 2012-05-30 2013-12-18 博瑞生物医药技术(苏州)有限公司 手性8-（3-氨基哌啶-1-基）-黄嘌呤的制备方法
CN103450201B (zh) * 2012-05-30 2017-04-12 博瑞生物医药（苏州）股份有限公司 手性8‑（3‑氨基哌啶‑1‑基）‑黄嘌呤的制备方法
WO2014033746A3 (en) * 2012-08-17 2014-05-30 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of dipeptidylpeptidase inhibitors
CN105073749A (zh) * 2012-12-17 2015-11-18 迈兰实验室有限公司 制备利拉利汀的改进方法
CN104478880A (zh) * 2014-12-26 2015-04-01 浙江永太科技股份有限公司 作为dpp-iv抑制剂的双胍衍生物
CN104592235A (zh) * 2014-12-26 2015-05-06 浙江永太科技股份有限公司 一种制备作为二肽基肽酶-4抑制剂的化合物的中间体
CN104592234B (zh) * 2014-12-26 2016-01-20 浙江永太科技股份有限公司 一种作为二肽基肽酶-4抑制剂的化合物的制备方法
CN104592235B (zh) * 2014-12-26 2016-01-20 浙江永太科技股份有限公司 一种制备作为二肽基肽酶-4抑制剂的化合物的中间体
CN104592234A (zh) * 2014-12-26 2015-05-06 浙江永太科技股份有限公司 一种作为二肽基肽酶-4抑制剂的化合物的制备方法
CN104478879A (zh) * 2014-12-26 2015-04-01 浙江永太科技股份有限公司 一种作为二肽基肽酶-4抑制剂的化合物
CN104557935A (zh) * 2015-01-27 2015-04-29 江苏嘉逸医药有限公司 制备(r)-8-(3-氨基哌啶-1-基)-黄嘌呤的提纯方法
CN106188058A (zh) * 2015-05-29 2016-12-07 江苏天士力帝益药业有限公司 黄嘌呤衍生物
CN110590780A (zh) * 2019-10-29 2019-12-20 深圳市第二人民医院 治疗糖尿病的药物利拉利汀的制备方法
CN111187223A (zh) * 2020-03-09 2020-05-22 沧州那瑞化学科技有限公司 利拉利汀中间体2-氯甲基-4-甲基喹唑啉的合成方法

Also Published As

Publication number Publication date
AU2005300559B2 (en) 2012-08-02
EA200900536A1 (ru) 2010-04-30
PL2287164T3 (pl) 2014-07-31
PE20060921A1 (es) 2006-10-30
JP2008519005A (ja) 2008-06-05
KR20140068267A (ko) 2014-06-05
TWI374885B (en) 2012-10-21
KR101583264B1 (ko) 2016-01-11
EP1812438A1 (de) 2007-08-01
US9751855B2 (en) 2017-09-05
ZA200701996B (en) 2008-08-27
CN101048409B (zh) 2014-01-22
EP3029040A1 (de) 2016-06-08
AR051947A1 (es) 2007-02-21
TW201305166A (zh) 2013-02-01
IL211015A0 (en) 2011-04-28
DE102004054054A1 (de) 2006-05-11
IL182923A (en) 2013-09-30
CN107266449A (zh) 2017-10-20
US9499546B2 (en) 2016-11-22
MX344285B (es) 2016-12-13
DK2287164T5 (da) 2014-07-14
HK1109405A1 (zh) 2008-06-06
BRPI0517093B1 (pt) 2020-12-22
SG185967A1 (en) 2012-12-28
KR20130016414A (ko) 2013-02-14
EA200700974A1 (ru) 2007-10-26
NZ555324A (en) 2010-12-24
SI2287164T1 (sl) 2014-04-30
EP2287164A1 (de) 2011-02-23
SG189768A1 (en) 2013-05-31
JP2011201908A (ja) 2011-10-13
EP2287164B1 (de) 2014-01-22
WO2006048427A8 (de) 2007-08-02
US8541450B2 (en) 2013-09-24
IL182923A0 (en) 2007-09-20
CN103351388B (zh) 2016-08-24
UY29190A1 (es) 2006-06-30
NZ617916A (en) 2015-06-26
PE20100232A1 (es) 2010-03-29
AU2005300559A1 (en) 2006-05-11
US20170129872A1 (en) 2017-05-11
EA029039B1 (ru) 2018-02-28
US20130178485A1 (en) 2013-07-11
EP3029040B1 (de) 2019-04-03
MX2007005404A (es) 2007-05-16
CY1115036T1 (el) 2016-12-14
NZ589450A (en) 2012-06-29
KR101440796B1 (ko) 2014-09-22
ME01667B (me) 2014-09-20
US7820815B2 (en) 2010-10-26
KR20070085744A (ko) 2007-08-27
CA2586938A1 (en) 2006-05-11
HRP20140373T1 (en) 2014-05-23
JP5766661B2 (ja) 2015-08-19
EP2287164B9 (de) 2014-06-11
EA201200491A1 (ru) 2012-08-30
CN103351388A (zh) 2013-10-16
ES2458106T3 (es) 2014-04-29
US20150025089A1 (en) 2015-01-22
JP2012211174A (ja) 2012-11-01
HUE044308T2 (hu) 2019-10-28
CN107266449B (zh) 2022-06-07
US20090192314A1 (en) 2009-07-30
PL3029040T3 (pl) 2019-10-31
WO2006048427A1 (de) 2006-05-11
US8883805B2 (en) 2014-11-11
EA012163B1 (ru) 2009-08-28
HRP20140373T2 (hr) 2014-10-10
SG157371A1 (en) 2009-12-29
JP5063356B2 (ja) 2012-10-31
TW200621776A (en) 2006-07-01
CN102391267A (zh) 2012-03-28
EA016752B1 (ru) 2012-07-30
US20170029402A1 (en) 2017-02-02
MY145604A (en) 2012-03-15
BRPI0517093A (pt) 2008-09-30
ES2731334T3 (es) 2019-11-15
CA2586938C (en) 2017-01-03
DK3029040T3 (da) 2019-06-24
PT2287164E (pt) 2014-03-17
US20060142310A1 (en) 2006-06-29
DK2287164T3 (da) 2014-03-10
NO20071522L (no) 2007-05-22
UA100221C2 (en) 2012-12-10
EP3539956A1 (de) 2019-09-18
RS53166B (sr) 2014-06-30
ES2458106T9 (es) 2014-09-09
TR201908974T4 (tr) 2019-07-22
KR101383610B1 (ko) 2014-04-10
JP5947492B2 (ja) 2016-07-06
BRPI0517093B8 (pt) 2021-05-25
CN102127080A (zh) 2011-07-20
CN102432593A (zh) 2012-05-02
CN102127080B (zh) 2016-01-20

Similar Documents

Publication Publication Date Title
CN101048409A (zh) 手性8－(3－氨基－哌啶－1－基)－黄嘌呤的制备方法
HK1169983A (zh) 光学活性的3-(邻苯二甲酰亚氨基)哌啶及其制备方法
HK1190148A (zh) 手性8-(3-氨基-哌啶-1-基)-黄嘌呤的制备方法
HK1109405B (zh) 手性8-(3-氨基-哌啶-1-基)-黄嘌呤的制备方法
HK1160124A (zh) 手性8-(3-氨基-哌啶-1-基)-黄嘌呤的制备方法
HK1167645A (zh) 8-(3-氨基-哌啶-1-基)-黄嘌呤、其制备方法及其用途
AU2012205240A1 (en) Method for producing chiral 8-(3-amino-piperidin-1-yl)-xanthines

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1109405

Country of ref document: HK

C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: In Germany

Applicant after: BOEHRINGER INGELHEIM INTERNATIONAL GmbH

Address before: In Germany

Applicant before: Boehringer Ingelheim International GmbH

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1109405

Country of ref document: HK

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20140122